Last updated: May 27, 2026
PROTONIX IV suppliers: who manufactures pantoprazole IV, packaging partners, and contract manufacturing footprint
Protonix IV is pantoprazole sodium provided as an intravenous formulation. The commercial supply chain for Protonix IV is tied to pantoprazole API sourcing, sterile lyophilized/intermediate processing (depending on packaging form), vial-filling and sterile manufacture, and finished-goods distribution. Public supplier visibility for “Protonix IV” is constrained because FDA listing detail is split across: (1) Orange Book “applicant/labeler” and (2) drug establishment registration (drugs listed under facility identifiers), and (3) DMF-holder supply for the API and sterile intermediate.
At a “hard data” level, the only consistently citable “supplier” identifiers for Protonix IV across FDA systems are the FDA labeler (NDC/Orange Book), FDA registered drug establishments that manufacture and package the finished product, and any directly cross-referenced DMF holders for pantoprazole ingredients. Without a specific NDC strength/container for “Protonix IV” and without the FDA establishment/Orange Book extract for that exact presentation, a complete, accuracy-guaranteed supplier map cannot be produced.
What companies supply PROTONIX IV (pantoprazole sodium) as the labeled manufacturer?
Answer (labeler-level): The “supplier” most directly tied to regulatory submissions is the FDA labeler/applicant of record for the specific Protonix IV presentation on the Orange Book and SPL/NDC listing.
How to identify the labeled supplier for a specific PROTONIX IV presentation
- Orange Book: “Applicant” (and any approved NDA references) for the exact dosage form and strength.
- FDA SPL: NDC labeler for the exact vial size and package configuration.
Key point: “Protonix IV” is a brand naming convention. FDA “suppliers” differ by strength and unit configuration, so supplier names change when the presentation changes.
Which FDA-registered facilities manufacture PROTONIX IV sterile drug product?
Answer (facility-level): The manufacturing and packaging “suppliers” for Protonix IV are the FDA-registered drug establishments listed for the finished product (sterile manufacturing and packaging).
What to look for in FDA establishment data
- Finished dosage form: “manufacturing” vs “packaging” vs “labeling”
- Sterile operations category: sterile fill-finish and packaging steps
- Facility registration status and address continuity for the current FDA cycle
Key point: One brand can have multiple facilities across time, including alternate sites for filling and packaging.
Are PROTONIX IV suppliers different from oral pantoprazole suppliers?
Answer: Yes. Oral pantoprazole (tablets) and Protonix IV (intravenous) typically use different sterile manufacturing networks and often different fill-finish sites.
Why the supplier footprint differs
- IV needs sterile manufacturing and validated aseptic processing
- Oral manufacturing uses different process controls and facility capabilities
- Even when API is common, final drug product suppliers are usually not identical
Who supplies pantoprazole API for PROTONIX IV (DMF-linked sources)?
Answer (ingredient-level): Pantoprazole sodium API supply is typically associated with DMF-referenced API manufacturers. Those sources appear in FDA records as DMF holders and cross-references are tied to the approved application.
What matters for IV supply chain
- DMF type: API DMF vs formulation/processing DMF
- Particle size, polymorph control, and impurity profile specifications that can trigger approval dependencies
- Supply continuity and change-control history
Key point: “Who supplies the API” can’t be answered reliably without the exact Orange Book/DFA reference chain for the specific IV NDA and strength.
What patent and regulatory identifiers tie to PROTONIX IV suppliers?
Answer: Supplier identity is anchored to FDA identifiers: NDA, applicant, labeling, NDC, and establishment registrations.
Where supplier data lives
- Orange Book for applicant/labeling and exclusivity/patent association
- FDA SPL / NDC for labeler and package-level mapping
- Drug Establishment Registration and Listing for manufacturing and packaging facilities
- DMF references for API manufacturing sources
How does exclusivity or generic/authorized supply affect PROTONIX IV supplier availability?
Answer: Contracting for IV sterile product supply often changes when:
- Market demand shifts to authorized generics
- Long supply gaps trigger alternate site qualification
- Post-approval changes move fill-finish operations to additional facilities
Commercial implications
- Supplier concentration risk is higher in sterile injectables with limited qualified fill-finish capacity
- Alternate facility qualification drives lead time and regulatory update steps
Key Takeaways
- The most defensible “supplier” list for Protonix IV is built from (1) the FDA labeler/applicant of record for the exact IV presentation, plus (2) FDA-registered manufacturing/packaging facilities, plus (3) DMF-linked API sources referenced by the approved application.
- Brand-name “Protonix IV” does not map one-to-one to suppliers unless the exact NDC/presentation is fixed.
- For a complete supplier map with named companies and facilities, supplier identification must be tied to Orange Book + NDC presentation + FDA establishment registration for that same product.
FAQs
-
How can I find the FDA labeler for Protonix IV by NDC?
Use FDA SPL/NDC listing for the exact vial size and strength associated with “Protonix IV.”
-
Which FDA system lists Protonix IV manufacturing and packaging sites?
FDA drug establishment registration and listing data.
-
Do pantoprazole IV and pantoprazole tablet suppliers come from the same facilities?
Often no, because IV requires sterile manufacturing and fill-finish capabilities that differ from oral manufacturing.
-
How do I identify pantoprazole API suppliers for Protonix IV?
Through DMF references linked to the approved IV application and cross-referenced in FDA records.
-
Do supplier facilities change over time for Protonix IV?
Yes, alternate manufacturing or packaging sites can be added via post-approval changes and facility qualification updates.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- U.S. Food and Drug Administration. Drugs@FDA.
- U.S. Food and Drug Administration. Drug Registration and Listing System (DRLS) data.
- U.S. Food and Drug Administration. SPL and NDC directory.
